Exclusive-US FDA Taps Merck Drugs With Blockbuster Sales Potential for National Priority Vouchers

Merck's cholesterol ​pill enlicitide decanoate and its cancer therapy sacituzumab tirumotecan, or sac-TMT, have been tapped ...
Fierce Pharma

Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga ...
pharmaphorum

Good news for Amgen as Repatha reverses atherosclerosis

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...
pharmaphorum

Amgen pulls higher-priced Repatha to try to lift sales

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is to make ...